Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactiplantibacillus plantarum Lp05
- Development stage
- Preclinical
- Lead developer
- Wecare Probiotics
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactiplantibacillus plantarum Lp05 is a specific probiotic strain of live bacteria developed and manufactured by Wecare Probiotics Co., Ltd. [2-14, 4-13] It is classified as a probiotic biologic (live microorganism) and is being researched for its therapeutic potential. [2-14, 4-13] Clinical and preclinical studies are investigating its use in treating Helicobacter pylori infections and protecting against ethanol-induced liver injury. [1-4, 2-1, 4-3] The proposed mechanism of action involves modulating the gut microbiota, suppressing H. pylori through direct interaction, and consequently reducing associated inflammation and oxidative stress. [1-4, 2-6] Although it is being investigated for specific medical applications, as a probiotic strain, it is also available for use in dietary supplements and food products.
- Other names
- Lactobacillus plantarum Lp05植物乳植杆菌Lp05
Beyond the preview
Go deeper on Lactiplantibacillus plantarum Lp05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactiplantibacillus plantarum Lp05.